ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Merkel cell carcinoma: long-term outcomes after radiotherapy treatment.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMerkel cell carcinoma (MCC) is a rare, aggressive disease with high relapse and fatality rates. Radiotherapy (RT) is essential for local control, but published data on both initial treatment and relapse management remain limited. MATERIAL AND
methodsWe retrospectively analyzed 17 patients treated in a single-center with radical and adjuvant RT.
resultsAfter a mean follow-up of 44 months, five (29%) patients relapsed (mean time to relapse 5.8 months after RT). Four relapses were locoregional, occurring outside the RT field, and received local salvatge therapy. One relapse was distant. Three patients received up to three consecutive RT courses for locoregional progression without systemic therapy. Five (29%) patients died after a mean time of 35.2 months, four of them with active disease. Two deaths were due to disease progression.
conclusionsDespite optimal local treatment, relapse remains common and is linked to poor outcomes, such as distant progression and death. Our findings reinforce the need for close postoperative monitoring and early initiation of adjuvant RT. Outcomes after early relapse suggest a potential role for treatment intensification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.